Tiziana Life Sciences Ltd
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- TLSATiziana Life Sciences LTD0Calm
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Running, no new patientsPhase 254 patientsMain results: Sep 2026 - TLSATiziana Life Sciences LTD0Calm
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Signing up patientsPhase 255 patientsMain results: Apr 30, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 5 purchases
- Elrifi IvorChief Executive Officer · Aug 5, 2026Bought 237,616 sharesabout $238 thousand ·
- Elrifi IvorChief Executive Officer · Aug 4, 2026Bought 83,807 sharesabout $81 thousand ·
- Elrifi IvorChief Executive Officer · Aug 3, 2026Bought 667,000 sharesabout $667 thousand ·
- CERRONE GABRIELE MBoard member · Jul 21, 2026Bought 42,357 sharesabout $42 thousand ·
- CERRONE GABRIELE MBoard member · Jun 12, 2026Bought 15,000 sharesabout $17 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.